ARKG ETF
Sign in to calculate the ETF estimate.
ARK Genomic Revolution ETF (ARKG) News
The latest ARK Genomic Revolution ETF (ARKG) news in one feed: fund flows, rebalancing, price analysis and market-moving headlines, curated by BTI.
ARK Trims Big Tech and Adds Biotech, but One Day Is Not a Sector Call
ARK sold Alphabet, Palantir and Cloudflare across two funds while ARKG added biotech shares. The coordinated trades are notable, but incomplete disclosures and different fund mandates limit the sector-rotation conclusion.
10x Genomics Led ARK's Q3 Gains While Tesla Dragged Across Funds
ARK's third-quarter attribution shows 10x Genomics as the biggest contributor to ARKG and a major boost to ARKK, while Tesla weighed on three funds. The figures measure portfolio contribution, not standalone stock returns.
ARK’s Third Quarter Was Driven by a Few Big Winners and Tesla’s Drag
ARK’s third-quarter attribution report shows concentrated gains from 10x Genomics, Palantir and Nvidia, while Tesla and Rocket Lab weighed on several funds. Contribution figures are not standalone stock returns.
ARK's Third Quarter Was Powered by AI Biology, Not Its Famous Names
10x Genomics and other AI-linked biotech holdings drove ARK's third-quarter gains, while Tesla and Rocket Lab detracted. Contribution data show where fund performance actually came from.
ARK's Q3 Attribution Shows Concentrated AI and Biotech Bets
ARK's third-quarter winners included 10x Genomics, Twist, Tempus and Palantir, while Tesla and Rocket Lab detracted. The figures reveal concentration and theme exposure, not a forecast of future returns.
ARK's Third-Quarter Attribution Shows Concentrated Winners and Drags
ARK's quarterly attribution put 10x Genomics and Palantir among major contributors while Tesla and Rocket Lab hurt returns. The figures measure each holding's effect on a fund, not its standalone stock performance.
ARK’s Third-Quarter Winners Show How Concentration Cuts Both Ways
ARK’s funds benefited from gains in genomics, AI and software holdings during the third quarter, while Tesla and Rocket Lab detracted. Contribution data reveal how concentrated thematic portfolios can amplify both correct calls and setbacks.
Five High-Flying ETFs Reveal Concentration and Leverage Risk
ARKG, EWY, EWT, SMH and TQQQ surged in 2026, but their gains came with concentrated holdings, cyclical exposure or daily leverage.
ARKG Adds Four Biotech Positions While Trimming 10x Genomics
ARK Invest added Ionis, Veracyte, Beam and Scribe to its genomics ETF while trimming 10x Genomics. These transactions expose the fund to distinct drug-development and diagnostics catalysts, not a uniform biotech theme.